Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 16/20 | 0.47 |
| ▸ | CTSD | P07339 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051944 | 0.93 | ALDH1A1 (0.53) | ALDH1A1ENPEPCTSDL3MBTL1 | |
| SCHEMBL30052816 | 0.93 | ALDH1A1 (0.56) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL30445952 | 0.90 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL1863400 | 0.90 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL934498 | 0.90 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL934499 | 0.90 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL2543429 | 0.90 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL30668289 | 0.89 | MME (0.51) | ALDH1A1ENPEPCTSD | |
| SCHEMBL30592756 | 0.89 | ALDH1A1 (0.47) | ALDH1A1ENPEPCTSDL3MBTL1 | |
| SCHEMBL30051960 | 0.89 | ALDH1A1 (0.47) | ALDH1A1ENPEPCTSDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20240254211-A1 | PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE | PROTHENA BIOSCIENCES LTD (IE) | 2024-08-01 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| EP-1578253-B2 | PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC DISEASE | PROTHENA BIOSCIENCES LTD (IE) | 2022-09-28 | — | — | EP | disclosed |
| US-5500208-A | Oral compositions comprising a novel tripeptide | THE PROCTER & GAMBLE COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| WO-1995033764-A2 | ORAL COMPOSITIONS COMPRISING A NOVEL TRIPEPTIDE | PROCTER & GAMBLE (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ALDH1A1 3596/4885ENPEP 18/4885CTSD 503/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ALDH1A1 4110/4885ENPEP 5/4885CTSD 213/4885 |
| US-20240254211-A1 | PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE | SNCA, PARK7, GAP43 | ALDH1A1 3120/4885ENPEP 269/4885CTSD 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.